Table 1.

Demographic and clinical information for COVID-19 patients in different LDH level.

Covariate	LDH normal or decreased group (n = 1,696)		LDH elevated group (n = 55)		P -value
Age, year, mean ± SD	57.51 ± 14.36		63.66 ± 14.49		0.002
Sex
Female	890	52.50%	26	47.30%	0.447
Male	806	47.50%	29	52.70%
Comorbidity	487	60.30%	36	73.50%	0.066
Cardiovascular disease	331	41.00%	22	44.90%	0.587
Pulmonary disease	82	10.60%	5	13.90%	0.533
Nervous system disease	50	6.20%	4	8.20%	0.581
Endocrine disease	129	16.00%	6	12.20%	0.488
Malignancy	56	6.90%	3	6.10%	0.828
Digestive system disease	41	5.10%	4	8.20%	0.347
Illness status of COVID-19 on admission
Mild	649	38.30%	14	25.50%	<0.001
Common	770	45.40%	14	25.50%
Severe	260	15.30%	20	36.40%
Critical	17	1.00%	7	12.70%
The highest level of illness status at hospitalization
Mild and common	903	53.40%	5	9.30%	<0.001
Severe	756	44.70%	36	66.70%
Critical	33	2.00%	13	24.10%
The highest level of oxygen support
Low flow oxygen therapy	250	86.20%	6	33.30%	<0.001
High flow oxygen therapy	39	13.40%	7	38.90%
Tracheal intubation	1	0.30%	4	22.20%
ECMO	0	0.00%	1	5.60%
Symptoms when admitted to the hospital
Fever or myalgia	575	79.00%	35	79.50%	0.929
Respiratory system symptoms	588	80.80%	35	79.50%	0.842
Digestive system symptoms	74	10.20%	6	13.60%	0.444
Nervous system symptoms	24	3.30%	2	4.50%	0.655
CT score 1 in the first time	2.31 ± 0.71		2.58 ± 0.72		0.084
CT score 2 in the first time	2.30 ± 0.78		2.63 ± 0.65		0.053
CT total score in the first time	4.62 ± 1.28		5.21 ± 1.10		0.035
Antiviral therapy	811	99.10%	41	100.00%	0.552
Antibiotic therapy	484	99.40%	34	100.00%	0.646
Anticoagulation treatment	103	6.10%	21	38.20%	<0.001
Use of corticosteroid	90	5.30%	17	30.90%	<0.001
Death	8	0.50%	7	12.70%	<0.001
Follow-up days, mean ± SD	19.26 ± 8.893		22.96 ± 10.38		0.004